CN105861532A - Method for regulating DAT (dopamine) gene expression on basis of miRNA-491 (microribonucleic acid-419) - Google Patents
Method for regulating DAT (dopamine) gene expression on basis of miRNA-491 (microribonucleic acid-419) Download PDFInfo
- Publication number
- CN105861532A CN105861532A CN201610219113.XA CN201610219113A CN105861532A CN 105861532 A CN105861532 A CN 105861532A CN 201610219113 A CN201610219113 A CN 201610219113A CN 105861532 A CN105861532 A CN 105861532A
- Authority
- CN
- China
- Prior art keywords
- mirna
- cell
- dopamine
- dat
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
The invention relates to a method for regulating DAT (dopamine) transporter gene expression in cells. The method is characterized by comprising the following steps: increasing the quantity of the miRNA-491 in the cells to lower the expression of the DAT gene; or decreasing the quantity of the miRNA-491 in the cells to enhance the expression of the DAT gene. The invention also relates to application of the miRNA-491 in preparing drugs for regulating human cells to ingest DAT. The invention also relates to a composition for regulating human cells to ingest DAT. The composition comprises the miRNA-491 or an inhibitor thereof, and one or more of a pharmaceutically acceptable a carrier, an excipient, a diluter and an adjuvant.
Description
Technical field
The present invention relates to molecular biology and field of medicaments.More specifically it relates to regulation DAT
(DAT) Microrna (miRNA) of gene expression.
Background technology
Dopamine is one of most important neurotransmitter of central nervous system, by activating dopamine receptor,
Participate in the vital movements such as motor adjustment, emotion, cognition, drug dependence, Neuroendocrine regulation.Take the photograph again
Taking is the neurotransmitter normal mechanism that passes through that presynaptic membrane eliminates from synaptic space, psychoactive drug substance effect
An important mechanisms be block nerves mediator after presynaptic membrane discharges reuptake.Block reuptake,
The normal effect of neurotransmitter is exaggerated.The cell membrane sodium dependency reuptake mistake of DAT mediation
Cutting off of Cheng Shixian dopamine signal, the maintenance of neurocyte dopamine stable state is played most important by this
Effect.DAT gene 3 ' UTR contains the variable number tandem repeat of 3 to 11 copies
(VNTR), the change of VNTR copy number and idiopathy, attention deficit hyperactivity disorder, ethanol
The relations such as the protective effect with cocaine dependence, parkinson disease susceptibility and opposing nicotine dependence are close
Cut.
MiRNA is the strand non-coding tiny RNA of a class high conservative, by about 20-22 mononucleotide
Composition, is widely present in eukaryote, participates in post-transcriptional level or the regulation and control of translation skill.miRNA
Play an important role in eukaryotic gene regulates and controls, wide participation cell proliferation, break up, grow, generation
Thank, apoptosis and other multiple vital movements.MiRNA has well-conserved, timing and tissue
The features such as specificity, by combination not fully complementary with target gene, a kind of multiple target of miRNA scalable
Gene expression.At present, in human body, hundreds of miRNA its sequence known have been found.
The present invention is exactly based on and finds in the gene regulation path participating in neurocyte picked-up dopamine
MiRNA, and the amount of such miRNA in neurocyte that regulates realize regulate neurocyte to DOPA
The amount of the dopamine in the picked-up of amine and then regulation neurocyte.
Summary of the invention
The technical scheme is that
A kind of method of DAT (DAT) gene expression regulated in cell, it is characterised in that
Including Microrna-491 (miRNA-491) (the SEQ ID NO:1) content improved in described cell
Thus lower the expression of described DAT gene；Or reduce the amount of miRNA-491 in described cell, thus
Raise the expression of described DAT gene.By the DAT gene expression in regulating cell, scalable cell
Picked-up to dopamine.
Further, the amount improving the miRNA-491 in described cell can be by by miRNA-491 mould
Intend thing (SEQ ID NO:2) transfection to carry out to described cell；Reduce in described cell
The amount of miRNA-491 can be by by the most described for miRNA-491 inhibitor (SEQ ID NO:3) transfection
Cell is carried out.
Further, described cell can be human nerve cell.
Present invention also offers miRNA-491 in preparation reduces the medicine of people's cellular uptake dopamine
Purposes, described miRNA-491 can be presented as miRNA-491 analogies, or miRNA-491 gene
The genetic constructs being built into strong promoter.
Present invention also offers miRNA-491 inhibitor and increase the medicine of people's cellular uptake dopamine in preparation
Purposes in thing, described miRNA-491 inhibitor can be presented as miRNA-491 antisense sequences, or
The genetic constructs that miRNA-491 antisense sequences gene is built into strong promoter.
Present invention also offers the compositions of a kind of amount for regulating people's cellular uptake dopamine, it comprises
MiRNA-491 or its inhibitor, and also comprise pharmaceutically acceptable supporting agent, excipient, diluent,
One or more in adjuvant.
Accompanying drawing explanation
Fig. 1 is psiCHECK2 plasmid map, and 3 ' UTR VNTR sequences of DAT gene are along transcribing
Direction is inserted between multiple clone site Xho I and Not I；
Fig. 2 is that sign has transfected with DAT gene 3 ' UTR VNTR sequence psiCHECK2 plasmid also
And transfected miRNA-491 analogies (miR-491), miRNA-491 inhibitor respectively
(anti-miR-491) relative luciferase activity or in the cell of comparison miRNA (ctl-miR)
Block diagram；
Fig. 3 has transfected miRNA-491 analogies (miR-491) respectively for sign, miRNA-491 presses down
Relative to mRNA activity in the cell of preparation (anti-miR-491) or comparison miRNA (ctl-miR)
Block diagram；
Fig. 4 is for having transfected miRNA-491 analogies (miR-491), miRNA-491 inhibitor respectively
And the total protein of cell of comparison miRNA (ctl-miR) is with anti-DAT antibody (anti-miR-491)
It it is an anti-western trace done；
Fig. 5 has transfected miRNA-491 analogies (miR-491) respectively for sign, miRNA-491 presses down
Preparation (anti-miR-491) with comparison miRNA (ctl-miR) cell in relative to dopamine level
Block diagram.
In the block diagram of the figures above, * p < 0.05, * * p < 0.01, * * * p < 0.001.
Detailed description of the invention
Being described principle and the feature of the present invention below in conjunction with accompanying drawing, example is served only for explaining this
Invention, is not intended to limit the scope of the present invention.
In the present invention, inventor use miRanda (http://www.microrna.org) obtain about
The information of forecasting of the miRNA target gene of the mankind, fruit bat and Brachydanio rerio genome and miRNA be not
With the express spectra of tissue, use TargetScan (http://www.targetscan.org) based on said target mrna
The miRNA target gene of the feature prediction animals such as the evolution conservative of sequence, it was unexpectedly found that, DAT
The VNTR of 3 ' UTR of gene exists the possible action target spot of miRNA-491.On the basis of this,
By luciferase expression activity analysis, mRNA and protein level analysis, functional level analysis,
Confirm eventually to regulate the expression of DAT gene, and then control by the amount of miRNA-491 in regulation cell
Make intracellular dopamine concentration.
MiRNA analogies are the double-strand oligoribonucleotides of a kind of synthesis, and wherein a chain is for having phase
Answer the chain of the sequence of miRNA, another chain reverse complemental chain, and, there is corresponding miRNA
There is on the chain of sequence end modified nucleotide analog.When miRNA analogies are transfected to cell
After in, reverse complemental chain is degraded by RNase present in intracellular environment at once, and has miRNA
The chain of sequence keeps not being degraded for a long time because of such modification, thereby increases the half of miRNA
Decline the phase, improve the valid density of miRNA.
MiRNA inhibitor and miRNA analogies contrast, it has end on reverse complemental chain
The nucleotide analog modified.After in miRNA analogies transfection to cell, there is miRNA sequence
The chain of row is degraded by RNase present in intracellular environment at once, and reverse complemental chain is because such
Modify and keep not being degraded for a long time, thereby increase the half-life of reverse complemental chain, improve reversely
The valid density of complementary strand.Corresponding interior miRNAs in reverse complemental chain combination cell so that it is can not
Function, thus reduce the valid density of miRNA.
Herein and in appended claims and sequence table, for miRNA-491 analogies and
Sequence shown by miRNA-491 inhibitor is all its ordered sequence, i.e. after in transfection to cell not
The sequence of that chain being decomposed.
In the present invention, by miRNA-491 analogies or miRNA-491 inhibitor are transfected to carefully
In born of the same parents, to improve or to reduce the amount of the miRNA-491 in cell, thus lower or raise DAT base
The expression of cause, thus affect the cell picked-up to dopamine.
MiRNA analogies and inhibitor are on sale in many biochemical reagents companies, and sequence maybe can be provided to allow life
Change company synthesizes, such as Tian Gen biochemical technology company, Guangzhou Ribo Bio Co., Ltd. etc..This
The miRNA-491 analogies used in inventive embodiments and inhibitor are purchased from the sharp rich biotechnology in Guangzhou
Company limited.
Materials and methods
Following methods is the conventional method of experiment, can carry out repairing of some necessity during specific experiment
Change.
1. cell is cultivated
By SK-N-SH neuroblastoma (deriving from American Type Culture collection warehousing, ATCC HTB-11)
It is inoculated in the MEM culture medium of the Sodium Pyruvate that with the addition of 10% hyclone and 0.1g/L, at 37 DEG C
And 5%CO2Lower cultivation.
2. plasmid construction and transfection
Use cellular genome is template, is obtained 3 ' UTR VNTR of DAT gene by PCR amplification
The fragment (about 2kb) of (SEQ ID NO:4), by this fragment insert psiCHECK2 plasmid (Promega,
Madison, WI, USA) multiple clone site XhoI of (Fig. 1) luciferase reporter gene hRluc upstream
And between NotI.Book according to the manufacturer's instructions, use Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) plasmid of the sequence of 3 ' the UTR VNTR with DAT gene turns by reagent
Contaminate in SK-N-SH neuroblastoma.
3.miRNA-491 analogies or the transfection of inhibitor
MiRNA-491 analogies and inhibitor are purchased from Guangzhou Ribo Bio Co., Ltd..According to system
Making the description of business, use Lipofectamine RNAiMAX reagent (Invitrogen) will
MiRNA-491 analogies or inhibitor transfection are to the above-mentioned SK-N-SH god with psiCHECK2 plasmid
In blastoma.Transfection method is as follows:
1) day before transfection growth medium inoculating cell without antibiotic, cell density
5×104/ ml, 100 μ l/ holes (as a example by 96 orifice plates), enable Flat single layer cell density during transfection
Reach about 70%；
2) serum free culture system liquid dilution miRNA is subtracted by amount Opti-MEM of every hole 10 μ l so that it is
Working concentration when finally hatching is 50-250nM；
3) transfection reagent Lipofectamine RNAiMAX is first gently mixed before using, then by every hole
Amount Opti-MEM of 10 μ l subtracts serum free culture system liquid and dilutes 0.2 μ l transfection reagent, softly mixes；
4) transfection reagent diluted and miRNA are mixed, cumulative volume 20 μ l, softly mix
Close, incubated at room 10 to 20 minutes；
5) in the culture plate containing cell and culture medium, every hole adds 20 μ l mixture, swings thin gently
Born of the same parents' culture plate mix homogeneously；
6) CO of constant temperature 37 DEG C2Complete transfection after incubator being hatched 24 to 72 hours, collect cell
For analyzing further.
Embodiment
Embodiment 1. luciferase reporter gene expression activity is analyzed
Use Dual-luciferase Reporter Assay System (Promega, E1910), according to manufacture
Business's description analyzes the psiCHECK2 matter wherein transfected with DAT gene 3 ' UTR VNTR
Grain and transfected miRNA-491 analogies, miRNA-491 inhibitor and negative control double-strand respectively
MiRNA (also is available from Guangzhou Ribo Bio Co., Ltd., transfection method and miRNA-491 mould
Intend thing or inhibitor identical) SK-N-SH neuroblastoma in relative luciferase activity.
Result is as in figure 2 it is shown, transfected in the cell (miR-491) of miRNA-491 analogies, glimmering
Light element enzymatic activity is about 50% (p < 0.01) in comparison (ctl-miR), and has transfected miRNA-491
In the cell (anti-miR-491) of inhibitor, uciferase activity is 1.1 in comparison (ctl-miR)
About times (p < 0.05).This result explanation miRNA-491 analogies are by DAT gene 3 ' UTR
The expression of VNTR Fluorophotometry element enzyme；And miRNA-491 inhibitor promotes the expression of this enzyme.
The horizontal analysis of embodiment 2.mRNA
Use luciferase reporter gene expression plasmid transfection SK-N-SH cell, hatch 5 hours, so
Rear respectively with miRNA-491 analogies or inhibitor transfection, hatch 48 hours.24 are cultivated after transfection
Hour, then by using SV Total RNAIsolation System (Promega) to extract RNA,
Use GoScript Reverse Transcription System that RNA reverse transcription is become cDNA, gained
CDNA dilute 10 times, carry out real-time quantitative PCR, CFX96Real-time System (Bio-Rad,
California, USA), use SYBR Premix Ex Taq Kit (TAKARA, Dalian, China),
With GAPDH as internal standard, analyze mrna expression level.
Result as it is shown on figure 3, transfected in the cell (miR-491) of miRNA-491 analogies, DAT
Mrna expression is about 30% (p < 0.001) in comparison (ctl-miR), and transfects
In the cell (anti-miR-491) of miRNA-491 inhibitor, mrna expression level is comparison
(ctl-miR) about about 1.8 times (p < 0.01) in.This result explanation miRNA-491 analogies fall
The activity of this mRNA low；And miRNA-491 inhibitor improves the expression of this mRNA.
Embodiment 3.DAT protein expression level is analyzed
After cultivating 24 hours, with RIPA cell pyrolysis liquid (25mM Tris-HCl, 150mM NaCl, 1%
NP-40,1% NaTDC, 0.1%SDS, pH 7.6) process cell sample, carry out 12%
SDS-PAGE electrophoresis,
Then carry out western trace, the albumen on gel is transferred to pvdf membrane (Millipore,
Bedford, MA) on, close.One anti-use mouse-anti people's DAT antibody (1:1 000 1:2 000, Abcam,
USA, Product code:ab5990, ab111468), and two anti-use mountain sheep anti mouses (1:1,000；Cell
Signaling Technology Inc.,Beverly,Massachusetts,USA).Equal-volume mixing Luminol
Luminescent solution is prepared, to transferred with protein with Peroxide reagent (Thermo Fisher Scientific)
Luminescent solution, gel imaging instrument ChemiDoc MP Imaging System is dripped on one pvdf membrane
Exposure colour developing in (Bio-Rad, Hercules, CA, USA).
Result as shown in Figure 4, compared with the cell having transfected comparison miRNA, has transfected miRNA-491
Cell in, DAT protein content reduces, and has transfected in the cell of miRNA-491 inhibitor, DAT
Protein content raises.This result illustrates, miRNA-491 analogies reduce the expression of DAT albumen, and
MiRNA inhibitor improves the expression of DAT albumen.
The analysis of embodiment 4. dopamine concentration
Cell is coated 24 hole culture dishs (200,000 cells/well), with miRNA-491 analogies,
MiRNA-491 inhibitor and negative control double-strand miRNA transfect, and hatch 48 hours.Then
Cell and 5 μ g/ml dopamine hydrochlorides are hatched 5 hours, uses dopamine ELISA kit
(Elabscience, Wuhan, Hubei, China, Product code:E-EL-0046c) measures intracellular many
Bar amine concentration.
Result is as it is shown in figure 5, transfected in the cell (miR-491) of miRNA-491 analogies, many
Bar amine is about 50% (p < 0.001) in comparison (ctl-miR), and has transfected miRNA-491 and pressed down
In the cell (anti-miR-491) of preparation, dopamine slightly above comparison (ctl-miR), but do not unite
Significance learned by meter.The explanation miRNA-491 simulation of this result makes the dopamine in neurocyte SK-N-SH
Concentration reduces；And miRNA-491 inhibitor is little on dopamine concentration impact.
Pass through above example, it was demonstrated that the transfection of miRNA-491 analogies can reduce cell to many
The picked-up of bar amine, therefore miRNA-491 analogies can be used for reducing people's cellular uptake dopamine, and
Can be used for preparation and reduce the medicine of people's cellular uptake dopamine；Demonstrate miRNA-491 inhibitor simultaneously
Transfection can increase the cell picked-up to dopamine, therefore miRNA-491 inhibitor can be used for increasing
People's cellular uptake dopamine, and can be used for the medicine of preparation reduction people's cellular uptake dopamine.
Present invention further contemplates the compositions for reducing people's cellular uptake dopamine, it comprises miRNA
Analogies, and also pharmaceutically acceptable supporting agent, excipient, diluent or adjuvant can be comprised.
The foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, all in the present invention
Spirit and principle within, any modification, equivalent substitution and improvement etc. made, should be included in this
Within bright protection domain.
Claims (6)
1. the method that the dopamine transporter gene that a kind regulates in cell is expressed, it is characterised in that include
Following steps: improve the amount of the miRNA-491 in described cell thus lower described DAT
The expression of gene；Or reduce the miRNA-491 amount in described cell, thus raise described dopamine and turn
The expression of fortune body gene, the sequence of described miRNA-491 is as shown in SEQ ID NO:1.
Method the most according to claim 1, it is characterised in that in the described cell of described raising
The amount of miRNA-491 is by carrying out the transfection of miRNA-491 analogies to described cell, described
The sequence of miRNA-491 analogies is as shown in SEQ ID NO:2.
Method the most according to claim 1, it is characterised in that in the described cell of described reduction
The amount of miRNA-491 is by carrying out the transfection of miRNA-491 inhibitor to described cell, described
The sequence of miRNA-491 is as shown in SEQ ID NO:3.
4. according to the method according to any one of claim 1-3, it is characterised in that described cell is behaved
Neurocyte.
5.miRNA-491 and inhibitor thereof regulate the application of the medicine of people's cellular uptake dopamine in preparation.
6. the compositions absorbing dopamine for regulating human nerve cell, it is characterised in that comprise
In miRNA-491 or its inhibitor, and pharmaceutically acceptable supporting agent, excipient, diluent, adjuvant
One or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610219113.XA CN105861532A (en) | 2016-04-08 | 2016-04-08 | Method for regulating DAT (dopamine) gene expression on basis of miRNA-491 (microribonucleic acid-419) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610219113.XA CN105861532A (en) | 2016-04-08 | 2016-04-08 | Method for regulating DAT (dopamine) gene expression on basis of miRNA-491 (microribonucleic acid-419) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105861532A true CN105861532A (en) | 2016-08-17 |
Family
ID=56636104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610219113.XA Pending CN105861532A (en) | 2016-04-08 | 2016-04-08 | Method for regulating DAT (dopamine) gene expression on basis of miRNA-491 (microribonucleic acid-419) |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105861532A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021004145A1 (en) * | 2019-07-05 | 2021-01-14 | 深圳市康宁医院(深圳市精神卫生研究所、深圳市精神卫生中心) | Use of mir-132 and 212 in preparation of drug for treating addiction |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102002489A (en) * | 2009-09-02 | 2011-04-06 | 中国科学院微生物研究所 | MicroRNA for inhibiting multiplication of H1N1 influenza virus and application thereof |
| WO2013067362A1 (en) * | 2011-11-04 | 2013-05-10 | Memorial Sloan-Kettering Cancer Center | Midbrain dopamine (da) neurons for engraftment |
-
2016
- 2016-04-08 CN CN201610219113.XA patent/CN105861532A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102002489A (en) * | 2009-09-02 | 2011-04-06 | 中国科学院微生物研究所 | MicroRNA for inhibiting multiplication of H1N1 influenza virus and application thereof |
| WO2013067362A1 (en) * | 2011-11-04 | 2013-05-10 | Memorial Sloan-Kettering Cancer Center | Midbrain dopamine (da) neurons for engraftment |
Non-Patent Citations (1)
| Title |
|---|
| 丛潇怡: "miR-491-5p调控DAT基因表达干预药物成瘾基质的研究", 《道客巴巴》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021004145A1 (en) * | 2019-07-05 | 2021-01-14 | 深圳市康宁医院(深圳市精神卫生研究所、深圳市精神卫生中心) | Use of mir-132 and 212 in preparation of drug for treating addiction |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7103653B2 (en) | Compounds, compositions, methods and kits for telomere elongation | |
| JP7277494B2 (en) | Methods and compositions for increasing somatic cell nuclear transfer (SCNT) efficiency by removing histone H3-lysine trimethylation | |
| AU2023204662A1 (en) | Nucleic acid products and methods of administration thereof | |
| AU2008286249B2 (en) | Efficient method for nuclear reprogramming | |
| CN109526226A (en) | Composition related with the expression therapeutic cells system of exogenous RNA and method | |
| JP2018530349A (en) | Methods and compositions for increasing the efficiency of human somatic cell nuclear transfer (SCNT) by eliminating histone H3-lysine trimethylation, and methods for inducing human NT-ESC | |
| CN109312339A (en) | For treating the material and method of amyotrophic lateral sclerosis and/or frontotemporal lobar degeneration | |
| TW202118873A (en) | Compositions and methods for treatment of disorders associated with repetitive dna | |
| Salahpour et al. | Local knockdown of genes in the brain using small interfering RNA: a phenotypic comparison with knockout animals | |
| CN107207557B (en) | method for regulating m6A modification level by miRNA and application thereof | |
| CN105755027A (en) | Method for regulating expression of DAT gene based on miRNA137 | |
| CN105861532A (en) | Method for regulating DAT (dopamine) gene expression on basis of miRNA-491 (microribonucleic acid-419) | |
| Le Marois et al. | RNA therapeutics for mood disorders: current evidence toward clinical trials | |
| KR20140046339A (en) | Method for differentiation into retinal cells from stem cells using inhibition of mirna-203 | |
| JP2014143923A (en) | Method for constructing functional nucleic acid molecules | |
| Pulcrano et al. | Lmx1a-dependent activation of miR-204/211 controls the timing of Nurr1-mediated dopaminergic differentiation | |
| CN110358777A (en) | The application of migratory locusts HMGR gene and its dsRNA in migratory locusts prevent and treat | |
| Sun et al. | Wybutosine hypomodification of tRNAphe activates HERVK and impairs neuronal differentiation | |
| Wijesinghe et al. | Adult porcine (Sus scrofa) derived inner ear cells possessing multipotent stem/progenitor cell characteristics in in vitro cultures | |
| Ko et al. | Reduced Cytotoxicity by Repetitive mRNA Transfection in Differentiated Neurons | |
| Gong et al. | MiRNA-let-7b decreases proliferation activities and development of follicular cells via targeting MAP3K1 gene | |
| KR102091511B1 (en) | Method of promoting stem cell differentiation efficiency | |
| US10246681B2 (en) | Reprogramming of human wharton's jelly cells to produce hair cells | |
| CN108913710A (en) | The plasmid and its construction method and purposes of nerve stem cell directional differentiation | |
| Uyhazi | Pumilio proteins regulate translation in embryonic stem cells and are essential for early embryonic development |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160817 |
|
| WD01 | Invention patent application deemed withdrawn after publication |